Cormica, a leading global medical device and pharmaceuticals testing group, has announced the acquisition of Focus Laboratories, which operates facilities in Allentown, Pennsylvania, and Palm Harbor, Florida.

Founded in 1996, Focus Laboratories was acquired in 2016 by Tony Grilli and specializes in microbiological testing, including rapid microbiology and consulting for the pharmaceutical, biotech, and medical device sectors. 

Focus Laboratories’ founder, Tony Grilli, will remain in his leadership role, ensuring continuity for the team and clients.

The acquisition will enable the business to leverage Cormica’s broader capabilities and resources, fostering organic growth and innovation. This also follows Cormica’s acquisition of Zwisler Laboratorium in Reichenau, in the south of Germany and furthers Cormica’s strategic goal of expanding its footprint across the US and Europe.

Mark Hammond, CEO of Cormica Group, commented: “We have had a strong start to 2025, with the acquisition of Zwisler Laboratorium and now Focus Laboratories which underscores our commitment to building a strong presence in the US. Focus has an outstanding reputation in microbiological testing, and we look forward to working closely with Tony Grilli and his team to support their future growth.”

Focus Laboratories will benefit from Cormica’s New Jersey chemistry facility, TPM Laboratories, enabling it to offer clients a more comprehensive portfolio of tests essential for developing and bringing lifesaving medicines and devices to market. Cormica’s acquisition of TPM Laboratories last year was its first in the US.

Anthony Grilli, founder of Focus Laboratories, said: “This partnership significantly expands our service offering, giving us access to invaluable resources and expertise that will allow us to serve more of our clients’ evolving needs while maintaining the exceptional quality and reliability they’ve come to expect from us. With a state-of-the-art analytical chemistry lab in New Jersey, we are now able to provide a more comprehensive suite of services critical to the development and market release of lifesaving medicines and devices.”